Spots Global Cancer Trial Database for dinaciclib
Every month we try and update this database with for dinaciclib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT01096342 | Refractory Mult... | dinaciclib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155) | NCT02684617 | rrCLL rrMM rrDLBCL | pembrolizumab dinaciclib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974) | NCT01650727 | Chronic Lymphoc... Small Lymphocyt... | Dinaciclib Rituximab | 18 Years - | Merck Sharp & Dohme LLC | |
| Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | NCT01711528 | Recurrent Plasm... | Bortezomib Dexamethasone Dinaciclib Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974) | NCT01650727 | Chronic Lymphoc... Small Lymphocyt... | Dinaciclib Rituximab | 18 Years - | Merck Sharp & Dohme LLC | |
| Dinaciclib in Treating Patients With Stage IV Melanoma | NCT00937937 | Acral Lentigino... Cutaneous Nodul... Lentigo Maligna... Low-CSD Melanom... Mucosal Melanom... Recurrent Melan... Stage IV Cutane... | Dinaciclib | 18 Years - | National Cancer Institute (NCI) | |
| Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer | NCT01676753 | Advanced or Met... Triple Negative... | Dinaciclib Pembrolizumab | 18 Years - 85 Years | University of California, San Francisco | |
| Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery | NCT01783171 | Pancreatic Aden... Recurrent Pancr... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Akt Inhibitor M... Dinaciclib Laboratory Biom... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | NCT01711528 | Recurrent Plasm... | Bortezomib Dexamethasone Dinaciclib Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia | NCT01515176 | Chronic Lymphoc... Prolymphocytic ... Recurrent Small... Refractory Chro... | Dinaciclib Laboratory Biom... Ofatumumab Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) | NCT01580228 | Chronic Lymphoc... | Dinaciclib Ofatumumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155) | NCT02684617 | rrCLL rrMM rrDLBCL | pembrolizumab dinaciclib | 18 Years - | Merck Sharp & Dohme LLC | |
| Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT01096342 | Refractory Mult... | dinaciclib laboratory biom... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
